search
Back to results

CBT for Anxiety Sensitivity vs. Disorder-specific CBT: An RCT

Primary Purpose

Generalized Anxiety, Stress Disorder, Posttraumatic, Social Anxiety

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cognitive Behavioural Therapy
Sponsored by
Sherry Stewart
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Generalized Anxiety

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Literate
  • High Anxiety Sensitivity (high AS, participants must score ≥23 on the Anxiety Sensitivity Index - 3)
  • Live in the surrounding area of Halifax, Nova Scotia or Fredericton, New Brunswick
  • Must have a primary diagnosis of one of Agoraphobia, Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder (PD), Other Specified Anxiety Disorder, Major Depressive Disorder (MDD), Posttraumatic Stress Disorder (PTSD), or Illness Anxiety Disorder (IAD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5; APA, 2013) as determined by a Structured Clinical Interview for DSM-5 Disorders

Exclusion Criteria:

  • Must not have any contraindications to physical exercise
  • Must not be engaged in another current psychotherapy as it may interfere with the treatment under investigation
  • Need to be able to attend intervention sessions at Dalhousie University or the University of New Brunswick
  • Must not have current Bipolar Disorder and psychosis nor current suicidal intent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Anxiety Sensitivity Cognitive Therapy

    Disorder specific Cognitive Therapy

    Arm Description

    Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.

    Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.

    Outcomes

    Primary Outcome Measures

    Change in anxiety sensitivity: the Anxiety Sensitivity Index - 3 (ASI-3)
    The ASI-3 is an 18-item self-report measure that indexes the amount of fear an individual experiences with respect to anxiety-related body sensations. Participants indicate the extent to which they agree or disagree with each item (e.g., "It scares me when my heart beats rapidly") on a 5-point Likert-type scale.
    Change in primary diagnosis (e.g., anxiety disorder or depression) symptoms
    Primary diagnosis (e.g., anxiety disorder or depression) symptoms, as measured by a standardized score on one of the Panic Attack Questionnaire - IV, the Fear Questionnaire, the Generalized Anxiety Disorder - 7-item, the Liebowitz Social Anxiety Scale, the PTSD Checklist for DSM-5, the Pain Anxiety Symptom Scale - 20-item, or the Patient Health Questionnaire - 9-item.
    Change in comorbid diagnosis (e.g., anxiety disorders or depression) symptoms
    Comorbid diagnosis (e.g., anxiety disorder or depression) symptoms, as measured by a standardized score on one of the Panic Attack Questionnaire - IV, the Fear Questionnaire, the Generalized Anxiety Disorder - 7-item, the Liebowitz Social Anxiety Scale, the PTSD Checklist for DSM-5, the Pain Anxiety Symptom Scale - 20-item, or the Patient Health Questionnaire - 9-item.

    Secondary Outcome Measures

    Diagnostic status as measured by the Structured Clinical Interview for DSM-5 (SCID-5)
    Administered by a trained researcher blind to treatment condition. The SCID-5 has been widely used in numerous research studies and is well empirically validated. At each time point, we will assess participants' primary and secondary diagnoses as well as the overall number of diagnoses for which they qualify.
    General distress as measured by the Depression Anxiety Stress Scale (DASS-21)
    The Depression Anxiety Stress Scales - 21. The DASS-21 is a shortened version of the 42-item DASS and is composed of three subscales: Depression, Anxiety, and Stress. Individuals indicate the extent to which a particular negative emotional state (e.g., "I found it difficult to relax") has applied to them over the past week on a 4-point Likert-type scale (0 = Did not apply to me at all to 3 = Applied to me very much or most of the time).
    General distress as measured by the Clinical Outcomes in Routine Evaluation measure (CORE-10)
    Clinical Outcomes in Routine Evaluation (CORE-10) is a brief, 10-item self-report measure designed to assess common presentations of symptoms of psychological distress. Participants are asked to indicate how often in the past week they have felt a series of symptoms (e.g., "I have felt tense, anxious, or nervous") on a 5-point Likert-type scale.
    Functional disability as measured by the Sheehan Disability Scale (SDS)
    The Sheehan Disability Scale will be used to measure functional impairment in three domains: work/school, family life, and social. Using a 10-point visual analogue scale, participants rate the extent to which their general mental health symptoms disrupt their work/school, family life/responsibilities, and social life. Participants also indicate the number of days their mental health symptoms caused them to miss school/work as well as the number of days their symptoms had caused their performance to be reduced during the past week. The SDS is well-validated and widely used with a range of populations.
    Drinking Motives as measured by the Modified Drinking Motives Questionnaire - Revised (MDMQ-R)
    The MDMQ-R measures drinking motives. Respondents estimate how often they drink for the reason specified in each item on a 5-point Likert-type scale.
    Hazardous alcohol use as measured by the Alcohol Use Disorders Identification Test (AUDIT)
    Despite being designed as a screening tool, the AUDIT is commonly used to assess alcohol use problems pre- and post-treatment. The AUDIT is a 10-item self-report measure that asks participants to report on their frequency of alcohol use, binge drinking, and alcohol-dependent behaviours. Responses are scored on 5-point Likert-type scales. Finally, participants report if they have experienced problems caused by alcohol use on a 3-point Likert-type scale.
    Alcohol-related problems as measured by the Short Inventory of Problems (SIP-2R)
    The SIP-2R consists of the three items from each of five subscales. Participants are asked to indicate the frequency with which they have experienced each of 15 drinking-related problems on a 4-point Likert-type scale.
    Treatment alliance as measured by the Working Alliance Inventory - Short-form (WAI-SR)
    The WAI-SR is a 12-item self-report questionnaire comprised of three subscales: Goals, or agreement on the goals of therapy, Tasks, or agreement on the tasks of therapy, and Bonds, or the bond between the therapist and the client. Participants indicate the extent to which each of these statements reflects their experience on a 5-point Likert-type scale.
    Treatment satisfaction as measured by several short researcher-generated questions
    In order to assess satisfaction with the different components of treatment, participants will answer a series of open-ended questions about their experience (e.g., "Was the treatment convenient for you to engage in?"; "Did you find the telephone therapy sessions helpful?") after all parts of treatment are completed (i.e., at 12 weeks).

    Full Information

    First Posted
    December 19, 2016
    Last Updated
    January 6, 2017
    Sponsor
    Sherry Stewart
    Collaborators
    University of New Brunswick, Canadian Institutes of Health Research (CIHR), Dalhousie University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03015285
    Brief Title
    CBT for Anxiety Sensitivity vs. Disorder-specific CBT: An RCT
    Official Title
    Comparing the Efficacy of CBT for Anxiety Sensitivity to Disorder-specific CBT in Reducing Mental Health Symptoms: A Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2017
    Overall Recruitment Status
    Unknown status
    Study Start Date
    January 2017 (undefined)
    Primary Completion Date
    August 2019 (Anticipated)
    Study Completion Date
    August 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Sherry Stewart
    Collaborators
    University of New Brunswick, Canadian Institutes of Health Research (CIHR), Dalhousie University

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Adults with high anxiety sensitivity (AS) and a mental health diagnosis of anxiety, depression, or posttraumatic stress will be recruited and will be randomly assigned to either transdiagnostic cognitive behavioural therapy (CBT) for AS or disorder-specific CBT for their primary mental health problem. The study outcomes - AS, anxiety, mood, and substance use symptoms, and functional impairment - will be assessed at pre-and post-treatment and 6 and 12 months post-treatment via standardized self-report measures completed by participants and a standardized diagnostic interview.
    Detailed Description
    While our previous work has provided some evidence that cognitive behavioural therapy (CBT) for anxiety sensitivity(AS) reduces mental health symptoms, the current study aims to determine whether this treatment works as well as traditional disorder-specific CBT (which aims to treat the specific disorder a person presents with, such as CBT for panic disorder for someone with panic disorder) in treating anxiety and depression. This will be the first study to have looked at this question. Our objectives are to determine: if there is a difference in the extent to which CBT for AS vs. disorder-specific CBT reduces, in the short- and long-term, a) AS, b) symptoms of a person's primary and secondary mental health problems, and c) functional disability (i.e., a person's ability to function in day-to-day life); if the two treatments lead to differences in the number of participants who no longer meet the requirements for a diagnosis (of their primary or secondary mental health problems) in the short- and long-term; and if the treatments are seen as similarly satisfactory by participants. Eligible participants will be randomly assigned (via online random number generator) to either transdiagnostic CBT for AS or disorder-specific CBT for their primary mental health problem. Both CBT interventions are evidence-based, guided by treatment manuals/workbooks (provided to participants), and involve 12 weekly therapy sessions. The AS intervention will also involve a physical exercise component (i.e., running/brisk walking 3x/week starting on week 5) and participants will be provided with a wearable fitness device designed to provide physiological indices of arousal and track physical activity. The study outcomes - AS, anxiety, mood, and substance use symptoms, and functional impairment - will be assessed at pre-and post-treatment and 6 and 12 months post-treatment via standardized self-report measures completed by participants and a standardized diagnostic interview.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Generalized Anxiety, Stress Disorder, Posttraumatic, Social Anxiety, Major Depression, Panic Disorder

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    136 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Anxiety Sensitivity Cognitive Therapy
    Arm Type
    Experimental
    Arm Description
    Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.
    Arm Title
    Disorder specific Cognitive Therapy
    Arm Type
    Active Comparator
    Arm Description
    Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Cognitive Behavioural Therapy
    Intervention Description
    A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
    Primary Outcome Measure Information:
    Title
    Change in anxiety sensitivity: the Anxiety Sensitivity Index - 3 (ASI-3)
    Description
    The ASI-3 is an 18-item self-report measure that indexes the amount of fear an individual experiences with respect to anxiety-related body sensations. Participants indicate the extent to which they agree or disagree with each item (e.g., "It scares me when my heart beats rapidly") on a 5-point Likert-type scale.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up.
    Title
    Change in primary diagnosis (e.g., anxiety disorder or depression) symptoms
    Description
    Primary diagnosis (e.g., anxiety disorder or depression) symptoms, as measured by a standardized score on one of the Panic Attack Questionnaire - IV, the Fear Questionnaire, the Generalized Anxiety Disorder - 7-item, the Liebowitz Social Anxiety Scale, the PTSD Checklist for DSM-5, the Pain Anxiety Symptom Scale - 20-item, or the Patient Health Questionnaire - 9-item.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up
    Title
    Change in comorbid diagnosis (e.g., anxiety disorders or depression) symptoms
    Description
    Comorbid diagnosis (e.g., anxiety disorder or depression) symptoms, as measured by a standardized score on one of the Panic Attack Questionnaire - IV, the Fear Questionnaire, the Generalized Anxiety Disorder - 7-item, the Liebowitz Social Anxiety Scale, the PTSD Checklist for DSM-5, the Pain Anxiety Symptom Scale - 20-item, or the Patient Health Questionnaire - 9-item.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up.
    Secondary Outcome Measure Information:
    Title
    Diagnostic status as measured by the Structured Clinical Interview for DSM-5 (SCID-5)
    Description
    Administered by a trained researcher blind to treatment condition. The SCID-5 has been widely used in numerous research studies and is well empirically validated. At each time point, we will assess participants' primary and secondary diagnoses as well as the overall number of diagnoses for which they qualify.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up
    Title
    General distress as measured by the Depression Anxiety Stress Scale (DASS-21)
    Description
    The Depression Anxiety Stress Scales - 21. The DASS-21 is a shortened version of the 42-item DASS and is composed of three subscales: Depression, Anxiety, and Stress. Individuals indicate the extent to which a particular negative emotional state (e.g., "I found it difficult to relax") has applied to them over the past week on a 4-point Likert-type scale (0 = Did not apply to me at all to 3 = Applied to me very much or most of the time).
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up
    Title
    General distress as measured by the Clinical Outcomes in Routine Evaluation measure (CORE-10)
    Description
    Clinical Outcomes in Routine Evaluation (CORE-10) is a brief, 10-item self-report measure designed to assess common presentations of symptoms of psychological distress. Participants are asked to indicate how often in the past week they have felt a series of symptoms (e.g., "I have felt tense, anxious, or nervous") on a 5-point Likert-type scale.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up
    Title
    Functional disability as measured by the Sheehan Disability Scale (SDS)
    Description
    The Sheehan Disability Scale will be used to measure functional impairment in three domains: work/school, family life, and social. Using a 10-point visual analogue scale, participants rate the extent to which their general mental health symptoms disrupt their work/school, family life/responsibilities, and social life. Participants also indicate the number of days their mental health symptoms caused them to miss school/work as well as the number of days their symptoms had caused their performance to be reduced during the past week. The SDS is well-validated and widely used with a range of populations.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up
    Title
    Drinking Motives as measured by the Modified Drinking Motives Questionnaire - Revised (MDMQ-R)
    Description
    The MDMQ-R measures drinking motives. Respondents estimate how often they drink for the reason specified in each item on a 5-point Likert-type scale.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up
    Title
    Hazardous alcohol use as measured by the Alcohol Use Disorders Identification Test (AUDIT)
    Description
    Despite being designed as a screening tool, the AUDIT is commonly used to assess alcohol use problems pre- and post-treatment. The AUDIT is a 10-item self-report measure that asks participants to report on their frequency of alcohol use, binge drinking, and alcohol-dependent behaviours. Responses are scored on 5-point Likert-type scales. Finally, participants report if they have experienced problems caused by alcohol use on a 3-point Likert-type scale.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up
    Title
    Alcohol-related problems as measured by the Short Inventory of Problems (SIP-2R)
    Description
    The SIP-2R consists of the three items from each of five subscales. Participants are asked to indicate the frequency with which they have experienced each of 15 drinking-related problems on a 4-point Likert-type scale.
    Time Frame
    baseline (i.e., start of study), 12 weeks, 6 months, and 12 months follow-up
    Title
    Treatment alliance as measured by the Working Alliance Inventory - Short-form (WAI-SR)
    Description
    The WAI-SR is a 12-item self-report questionnaire comprised of three subscales: Goals, or agreement on the goals of therapy, Tasks, or agreement on the tasks of therapy, and Bonds, or the bond between the therapist and the client. Participants indicate the extent to which each of these statements reflects their experience on a 5-point Likert-type scale.
    Time Frame
    Only at 12 weeks
    Title
    Treatment satisfaction as measured by several short researcher-generated questions
    Description
    In order to assess satisfaction with the different components of treatment, participants will answer a series of open-ended questions about their experience (e.g., "Was the treatment convenient for you to engage in?"; "Did you find the telephone therapy sessions helpful?") after all parts of treatment are completed (i.e., at 12 weeks).
    Time Frame
    Only at 12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    19 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Literate High Anxiety Sensitivity (high AS, participants must score ≥23 on the Anxiety Sensitivity Index - 3) Live in the surrounding area of Halifax, Nova Scotia or Fredericton, New Brunswick Must have a primary diagnosis of one of Agoraphobia, Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder (PD), Other Specified Anxiety Disorder, Major Depressive Disorder (MDD), Posttraumatic Stress Disorder (PTSD), or Illness Anxiety Disorder (IAD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5; APA, 2013) as determined by a Structured Clinical Interview for DSM-5 Disorders Exclusion Criteria: Must not have any contraindications to physical exercise Must not be engaged in another current psychotherapy as it may interfere with the treatment under investigation Need to be able to attend intervention sessions at Dalhousie University or the University of New Brunswick Must not have current Bipolar Disorder and psychosis nor current suicidal intent
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Sherry Stewart, PhD
    Phone
    9024943793
    Email
    sherry.stewart@dal.ca
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jennifer Swansburg, BSc
    Phone
    9024943793
    Email
    jennifer.swansburg@dal.ca
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Margo Watt, PhD
    Organizational Affiliation
    St. Francis Xavier University
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Janine Olthuis, PhD
    Organizational Affiliation
    University of New Brunswick
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    Data will only be shared between investigators at the two study sites once it has been de-identified and entered into a data analytic program in order to protect participants' privacy and confidentiality.

    Learn more about this trial

    CBT for Anxiety Sensitivity vs. Disorder-specific CBT: An RCT

    We'll reach out to this number within 24 hrs